ArticleThe Journal of infectious diseases2011
The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions.
Article in The Journal of infectious diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity.JAMA network open · 2022Trial
- Short communication: T cell activation in HIV-1/herpes simplex virus-2-coinfected Kenyan women receiving valacyclovir.AIDS research and human retroviruses · 2013Trial
- Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.Lancet (London, England) · 2012Trial
- Review
- Human Herpes Virus-8 Oral Shedding Heterogeneity Is Due to Varying Rates of Reactivation from Latency and Immune Containment.Viruses · 2025Article
- Highly Heterogeneous Kaposi Sarcoma-Associated Herpesvirus Oral Shedding Kinetics Among People With and Without Kaposi Sarcoma and Human Immunodeficiency Virus Coinfection.Open forum infectious diseases · 2024Article
- Local Power: The Role of Tissue-Resident Immunity in Human Genital Herpes Simplex Virus Reactivation.Viruses · 2024Review
- Article
- Comparison of herpes simplex virus 1 genomic diversity between adult sexual transmission partners with genital infection.PLoS pathogens · 2022Article
- Tissue-resident memory T cells in the urogenital tract.Nature reviews. Nephrology · 2022Review
- Release of HSV-1 Cell-Free Virions: Mechanisms, Regulation, and Likely Role in Human-Human Transmission.Viruses · 2021Review
- A holistic perspective on herpes simplex virus (HSV) ecology and evolution.Advances in virus research · 2021Review
- Tissue-resident T cell-derived cytokines eliminate herpes simplex virus-2-infected cells.The Journal of clinical investigation · 2020Article
- Correlation between detergent activity and anti-herpes simplex virus-2 activity of commercially available vaginal gels.BMC research notes · 2020Article
- Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.Vaccine · 2019Review
- Review of mathematical models of HSV-2 vaccination: Implications for vaccine development.Vaccine · 2019Review
- Increased Frequency of Virus Shedding by Herpes Simplex Virus 2-Infected Guinea Pigs in the Absence of CD4Journal of virology · 2019Article
- Acute Infection and Subsequent Subclinical Reactivation of Herpes Simplex Virus 2 after Vaginal Inoculation of Rhesus Macaques.Journal of virology · 2019Article
- Increase in HSV shedding at initiation of antiretroviral therapy and decrease in shedding over time on antiretroviral therapy in HIV and HSV-2 infected persons.AIDS (London, England) · 2018Observational
- Herpes simplex virus-2 dynamics as a probe to measure the extremely rapid and spatially localized tissue-resident T-cell response.Immunological reviews · 2018Review
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
backgroundHerpes simplex virus type 2 (HSV-2) reactivations in the genital tract are responsible for mucocutaneous lesions and transmission and manifest as discrete shedding episodes.
methodsWe analyzed duration, peak copy number, and expansion and decay rates of 1020 shedding episodes in 531 immunocompetent HSV-2-seropositive persons from whom daily swabs of genital secretions were collected.
resultsViral quantity varied by as much as a multiple of 10 million in a single person over time. Peak episode copy number was distributed approximately evenly from 10(3) through 10(8) HSV DNA copies/mL. Median rate of increase was 10(7.6) HSV DNA copies/day during the first 12 hours of an episode and 10(5) copies/d from episode initiation to peak. These values depended only moderately on episode duration. Median decay rate was -10(6.2) HSV DNA copies/d during the final 12 hours of an episode and -10(3.6) copies/d from peak to termination. Episodes lasted a median of 3 days (interquartile range, 1-8 days). Prolonged (>5 days) episodes were associated with nonmonotonic decay.
conclusionsHSV-2 shedding episodes are notable for rapid expansion and decay and extreme heterogeneity of duration and viral production. The net effect of these dynamic episodes is frequent shedding at high copy numbers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.